vaccine mkt saturated_老虎社区_美港股上老虎

evwaeng
2021-07-07

vaccine mkt saturated

COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO

July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and o

COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":140444216,"tweetId":"140444216","gmtCreate":1625670506435,"gmtModify":1633938488734,"author":{"id":3570269548399266,"idStr":"3570269548399266","authorId":3570269548399266,"authorIdStr":"3570269548399266","name":"evwaeng","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>vaccine mkt saturated&nbsp;</p></body></html>","htmlText":"<html><head></head><body><p>vaccine mkt saturated&nbsp;</p></body></html>","text":"vaccine mkt saturated","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/140444216","repostId":1128740137,"repostType":4,"repost":{"id":"1128740137","kind":"news","pubTimestamp":1625668639,"share":"https://ttm.financial/m/news/1128740137?lang=&edition=full","pubTime":"2021-07-07 22:37","market":"us","language":"en","title":"COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1128740137","media":"Reuters","summary":"July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and o","content":"<p>July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S. initial public offering (IPO).</p>\n<p>Founded by billionaire Sergio Stevanato, the company said in its filing that a total of 40 million shares would be offered for sale priced between $21 and $24 each. The IPO would raise $960 million at the top end of that range.</p>\n<p>About 30% of those shares will be offered by the Stevenato family holding, an existing investor. The proceeds from those shares will not go to the company.</p>\n<p>Padua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass manufacturer that was the precursor to the medical packaging company.</p>\n<p>The company started its international expansion in 2015 after the purchase of a primary packaging company in Slovakia.</p>\n<p>Stevanato, whose IPO plans were reported by Reuters in February, will list on the New York Stock Exchange under the symbol \"STVN\".</p>\n<p>Morgan Stanley, BofA Securities and Jefferies are the lead underwriters for the offering.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>COVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCOVID-19 vaccine vial maker Stevanato eyes $7 bln valuation in U.S. IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-07 22:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite"},"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/stevanato-group-maker-covid-19-vaccine-vials-eyes-7-bln-valuation-us-ipo-2021-07-07/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1128740137","content_text":"July 7 (Reuters) - Italy's Stevanato Group S.p.A., a maker of glass vials for COVID-19 vaccine and other healthcare products, said on Wednesday it was seeking a valuation of over $7 billion in its U.S. initial public offering (IPO).\nFounded by billionaire Sergio Stevanato, the company said in its filing that a total of 40 million shares would be offered for sale priced between $21 and $24 each. The IPO would raise $960 million at the top end of that range.\nAbout 30% of those shares will be offered by the Stevenato family holding, an existing investor. The proceeds from those shares will not go to the company.\nPadua-based Stevanato Group started in 1949 as Soffieria Stella, a specialty glass manufacturer that was the precursor to the medical packaging company.\nThe company started its international expansion in 2015 after the purchase of a primary packaging company in Slovakia.\nStevanato, whose IPO plans were reported by Reuters in February, will list on the New York Stock Exchange under the symbol \"STVN\".\nMorgan Stanley, BofA Securities and Jefferies are the lead underwriters for the offering.","news_type":1,"symbols_score_info":{".IXIC":0.9}},"isVote":1,"tweetType":1,"viewCount":662,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":19,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}